TY - JOUR
T1 - Structure-Based Design of Peptidic Inhibitors of the Interaction between CC Chemokine Ligand 5 (CCL5) and Human Neutrophil Peptides 1 (HNP1)
AU - Wichapong, Kanin
AU - Alard, Jean -Eric
AU - Ortega-Gomez, Almudena
AU - Weber, Christian
AU - Hackeng, Tilman M.
AU - Soehnlein, Oliver
AU - Nicolaes, Gerry A. F.
PY - 2016/5/12
Y1 - 2016/5/12
N2 - Protein-protein interactions (PPIs) are receiving increasing interest, much sparked by the realization that they represent druggable targets. Recently, we successfully developed a peptidic inhibitor, RRYGTSKYQ("SKY" peptide), that shows high potential in vitro and in vivo to interrupt a PPI between the platelet-borne chemokine CCL5 and the neutrophil-derived granule protein HNP1. This PPI plays a vital role in monocyte adhesion, representing a key mechanism in acute and chronic inflammatory diseases. Here, we present extensive and detailed computational methods applied to develop the SKY peptide. We combined experimentally determined binding affinities (K-D) of several orthologs of CCL5 with HNP1 with in silico studies to identify the most likely heterodimeric CCL5 HNP1 complex which was subsequently used as a starting structure to rationally design peptidic inhibitors. Our method represents a fast and simple approach that can be widely applied to determine other protein protein complexes and moreover to design inhibitors or stabilizers of protein-protein interaction.
AB - Protein-protein interactions (PPIs) are receiving increasing interest, much sparked by the realization that they represent druggable targets. Recently, we successfully developed a peptidic inhibitor, RRYGTSKYQ("SKY" peptide), that shows high potential in vitro and in vivo to interrupt a PPI between the platelet-borne chemokine CCL5 and the neutrophil-derived granule protein HNP1. This PPI plays a vital role in monocyte adhesion, representing a key mechanism in acute and chronic inflammatory diseases. Here, we present extensive and detailed computational methods applied to develop the SKY peptide. We combined experimentally determined binding affinities (K-D) of several orthologs of CCL5 with HNP1 with in silico studies to identify the most likely heterodimeric CCL5 HNP1 complex which was subsequently used as a starting structure to rationally design peptidic inhibitors. Our method represents a fast and simple approach that can be widely applied to determine other protein protein complexes and moreover to design inhibitors or stabilizers of protein-protein interaction.
U2 - 10.1021/acs.jmedchem.5b01952
DO - 10.1021/acs.jmedchem.5b01952
M3 - Article
C2 - 26871718
SN - 0022-2623
VL - 59
SP - 4289
EP - 4301
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 9
ER -